{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:07:56Z","timestamp":1786982876121,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40801-024-00422-5","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T04:01:47Z","timestamp":1712030507000},"page":"273-283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ceftaroline Fosamil for the Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia: A Real-World Comparative Clinical Outcomes Study"],"prefix":"10.1007","volume":"11","author":[{"given":"Jennifer","family":"Hammond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Benigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataly","family":"Bleibdrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1910-5836","authenticated-orcid":false,"given":"Wajeeha","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"issue":"21","key":"422_CR1","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1001\/jamainternmed.2013.10423","volume":"173","author":"R Dantes","year":"2013","unstructured":"Dantes R, Mu Y, Belflower R, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med. 2013;173(21):1970\u20138. https:\/\/doi.org\/10.1001\/jamainternmed.2013.10423.","journal-title":"JAMA Intern Med"},{"issue":"12","key":"422_CR2","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1093\/cid\/ciz123","volume":"69","author":"K Inagaki","year":"2019","unstructured":"Inagaki K, Lucar J, Blackshear C, Hobbs CV. Methicillin-susceptible and methicillin-resistant Staphylococcus aureus bacteremia: nationwide estimates of 30-day readmission, in-hospital mortality, length of stay, and cost in the United States. Clin Infect Dis. 2019;69(12):2112\u20138. https:\/\/doi.org\/10.1093\/cid\/ciz123.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"422_CR3","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-55. https:\/\/doi.org\/10.1093\/cid\/ciq146.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"422_CR4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/cid\/cir935","volume":"54","author":"SJ van Hal","year":"2012","unstructured":"van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755\u201371. https:\/\/doi.org\/10.1093\/cid\/cir935.","journal-title":"Clin Infect Dis"},{"key":"422_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2217\/fmb-2018-0346","volume":"14","author":"M Wilcox","year":"2019","unstructured":"Wilcox M, Al-Obeid S, Gales A, et al. Reporting elevated vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus: consensus by an International Working Group. Future Microbiol. 2019;14:345\u201352. https:\/\/doi.org\/10.2217\/fmb-2018-0346.","journal-title":"Future Microbiol"},{"issue":"5","key":"422_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1086\/520655","volume":"45","author":"HW Boucher","year":"2007","unstructured":"Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis. 2007;45(5):601\u20138. https:\/\/doi.org\/10.1086\/520655.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"422_CR7","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1128\/jcm.44.2.655-656.2006","volume":"44","author":"DJ Skiest","year":"2006","unstructured":"Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol. 2006;44(2):655\u20136. https:\/\/doi.org\/10.1128\/jcm.44.2.655-656.2006.","journal-title":"J Clin Microbiol"},{"key":"422_CR8","unstructured":"Infectious Diseases Society of America. Staphylococcus aureus bacteremia. 2020. https:\/\/www.idsociety.org\/practice-guideline\/staphylococcus-aureus-bacteremia\/. Accessed 1 July 2022."},{"issue":"5","key":"422_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/01.md.0000091184.93122.09","volume":"82","author":"FY Chang","year":"2003","unstructured":"Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore). 2003;82(5):333\u20139. https:\/\/doi.org\/10.1097\/01.md.0000091184.93122.09.","journal-title":"Medicine (Baltimore)"},{"key":"422_CR10","doi-asserted-by":"publisher","unstructured":"Kim SH, Kim KH, Kim HB et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008;52(1):192-7. https:\/\/doi.org\/10.1128\/aac.00700-07.","DOI":"10.1128\/aac.00700-07"},{"issue":"3","key":"422_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/cid\/civ308","volume":"61","author":"JS McDanel","year":"2015","unstructured":"McDanel JS, Perencevich EN, Diekema DJ, et al. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis. 2015;61(3):361\u20137. https:\/\/doi.org\/10.1093\/cid\/civ308.","journal-title":"Clin Infect Dis"},{"key":"422_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/1471-2334-11-279","volume":"11","author":"ML Schweizer","year":"2011","unstructured":"Schweizer ML, Furuno JP, Harris AD, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis. 2011;11:279. https:\/\/doi.org\/10.1186\/1471-2334-11-279.","journal-title":"BMC Infect Dis"},{"key":"422_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12941-016-0143-3","volume":"15","author":"D Wong","year":"2016","unstructured":"Wong D, Wong T, Romney M, Leung V. Comparative effectiveness of \u03b2-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Ann Clin Microbiol Antimicrob. 2016;15:27. https:\/\/doi.org\/10.1186\/s12941-016-0143-3.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"2","key":"422_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00109-013-1100-7","volume":"92","author":"G Sakoulas","year":"2014","unstructured":"Sakoulas G, Okumura CY, Thienphrapa W, et al. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J Mol Med (Berl). 2014;92(2):139\u201349. https:\/\/doi.org\/10.1007\/s00109-013-1100-7.","journal-title":"J Mol Med (Berl)"},{"issue":"5","key":"422_CR15","doi-asserted-by":"publisher","first-page":"e02483","DOI":"10.1128\/aac.02483-18","volume":"63","author":"M Geriak","year":"2019","unstructured":"Geriak M, Haddad F, Rizvi K, et al. Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2019;63(5):e02483-e2518. https:\/\/doi.org\/10.1128\/aac.02483-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"422_CR16","doi-asserted-by":"publisher","first-page":"e01043","DOI":"10.1128\/aac.01043-17","volume":"61","author":"HS Sader","year":"2017","unstructured":"Sader HS, Mendes RE, Streit JM, Flamm RK. Antimicrobial susceptibility trends among Staphylococcus aureus isolates from U.S. hospitals: results from 7 years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016. Antimicrob Agents Chemother. 2017;61(9):e01043-e1117. https:\/\/doi.org\/10.1128\/aac.01043-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"422_CR17","unstructured":"Pfizer. Zinforo 600 mg powder for concentrate for solution for infusion: summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/documents\/product-information\/zinforo-epar-product-information_en.pdf. Accessed 15 Mar 2023."},{"key":"422_CR18","unstructured":"Allergan. TEFLARO\u2122 (ceftaroline fosamil) injection for intravenous (IV) use. 2021. https:\/\/www.allergan.com\/assets\/pdf\/teflaro_pi. Accessed 15 Mar 2023."},{"key":"422_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijid.2017.01.019","volume":"57","author":"S Arshad","year":"2017","unstructured":"Arshad S, Huang V, Hartman P, Perri MB, Moreno D, Zervos MJ. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study. Int J Infect Dis. 2017;57:27\u201331. https:\/\/doi.org\/10.1016\/j.ijid.2017.01.019.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"422_CR20","doi-asserted-by":"publisher","first-page":"e02015","DOI":"10.1128\/aac.02015-16","volume":"61","author":"EJ Zasowski","year":"2017","unstructured":"Zasowski EJ, Trinh TD, Claeys KC, et al. Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2017;61(2):e02015-e2016. https:\/\/doi.org\/10.1128\/aac.02015-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"422_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2146\/ajhp160006","volume":"74","author":"BP White","year":"2017","unstructured":"White BP, Barber KE, Stover KR. Ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Am J Health Syst Pharm. 2017;74(4):201\u20138. https:\/\/doi.org\/10.2146\/ajhp160006.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"422_CR22","doi-asserted-by":"publisher","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","volume":"7","author":"EK McCreary","year":"2020","unstructured":"McCreary EK, Kullar R, Geriak M, et al. Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments. Open Forum Infect Dis. 2020;7(1):ofz538. https:\/\/doi.org\/10.1093\/ofid\/ofz538.","journal-title":"Open Forum Infect Dis"},{"key":"422_CR23","unstructured":"Premier Inc. White Paper. Premier Healthcare Database: Data That Informs and Performs. 2020. https:\/\/products.premierinc.com\/downloads\/PremierHealthcareDatabaseWhitepaper.pdf. Accessed 24 Apr 2023."},{"issue":"2","key":"422_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/cid\/cir340","volume":"53","author":"A Dhand","year":"2011","unstructured":"Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53(2):158\u201363. https:\/\/doi.org\/10.1093\/cid\/cir340.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"422_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1128\/aac.02071-15","volume":"60","author":"AD Berti","year":"2016","unstructured":"Berti AD, Theisen E, Sauer JD, et al. Penicillin binding protein 1 is important in the compensatory response of Staphylococcus aureus to daptomycin-induced membrane damage and is a potential target for \u03b2-lactam-daptomycin synergy. Antimicrob Agents Chemother. 2016;60(1):451\u20138. https:\/\/doi.org\/10.1128\/aac.02071-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"422_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/antibiotics8010030","volume":"8","author":"N Lounsbury","year":"2019","unstructured":"Lounsbury N, Reeber MG, Mina G, Chbib C. A mini-review on ceftaroline in bacteremia patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. Antibiotics (Basel). 2019;8(1):30. https:\/\/doi.org\/10.3390\/antibiotics8010030.","journal-title":"Antibiotics (Basel)."},{"issue":"1","key":"422_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/ciz746","volume":"71","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen SCJ, Zasowski EJ, Trinh TD, et al. Daptomycin plus \u03b2-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study. Clin Infect Dis. 2020;71(1):1\u201310. https:\/\/doi.org\/10.1093\/cid\/ciz746.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"422_CR28","first-page":"21","volume":"31","author":"JH Martin","year":"2010","unstructured":"Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. Clin Biochem Rev. 2010;31(1):21\u20134.","journal-title":"Clin Biochem Rev"},{"issue":"Suppl 1","key":"422_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1469-0691.2006.01344.x","volume":"12","author":"PC Appelbaum","year":"2006","unstructured":"Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2006;12(Suppl 1):16\u201323. https:\/\/doi.org\/10.1111\/j.1469-0691.2006.01344.x.","journal-title":"Clin Microbiol Infect"},{"key":"422_CR30","doi-asserted-by":"publisher","first-page":"41758","DOI":"10.1038\/srep41758","volume":"7","author":"CC Lai","year":"2017","unstructured":"Lai CC, Chen CC, Chuang YC, Tang HJ. Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA. Sci Rep. 2017;7:41758. https:\/\/doi.org\/10.1038\/srep41758.","journal-title":"Sci Rep"},{"issue":"2","key":"422_CR31","doi-asserted-by":"publisher","first-page":"e01554","DOI":"10.1128\/aac.01554-17","volume":"62","author":"J Truong","year":"2018","unstructured":"Truong J, Veillette JJ, Forland SC. Outcomes of vancomycin plus a \u03b2-lactam versus vancomycin only for treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2018;62(2):e01554-e1617. https:\/\/doi.org\/10.1128\/aac.01554-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"422_CR32","doi-asserted-by":"publisher","first-page":"734","DOI":"10.4161\/viru.26909","volume":"4","author":"J Seah","year":"2013","unstructured":"Seah J, Lye DC, Ng TM, Krishnan P, Choudhury S, Teng CB. Vancomycin monotherapy vs. combination therapy for the treatment of persistent methicillin-resistant Staphylococcus aureus bacteremia. Virulence. 2013;4(8):734\u20139. https:\/\/doi.org\/10.4161\/viru.26909.","journal-title":"Virulence."},{"issue":"2","key":"422_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/cid\/civ808","volume":"62","author":"JS Davis","year":"2016","unstructured":"Davis JS, Sud A, O\u2019Sullivan MVN, et al. Combination of vancomycin and \u03b2-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis. 2016;62(2):173\u201380. https:\/\/doi.org\/10.1093\/cid\/civ808.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"422_CR34","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jama.2020.0103","volume":"323","author":"SYC Tong","year":"2020","unstructured":"Tong SYC, Lye DC, Yahav D, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal \u03b2-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020;323(6):527\u201337. https:\/\/doi.org\/10.1001\/jama.2020.0103.","journal-title":"JAMA"},{"issue":"12","key":"422_CR35","doi-asserted-by":"publisher","first-page":"ofaa538","DOI":"10.1093\/ofid\/ofaa538","volume":"7","author":"J Liu","year":"2020","unstructured":"Liu J, Tong SYC, Davis JS, Rhodes NJ, Scheetz MH. Vancomycin exposure and acute kidney injury outcome: a snapshot from the CAMERA2 study. Open Forum Infect Dis. 2020;7(12):ofaa538. https:\/\/doi.org\/10.1093\/ofid\/ofaa538.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"422_CR36","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/cid\/ciac476","volume":"75","author":"SYC Tong","year":"2022","unstructured":"Tong SYC, Mora J, Bowen AC, et al. The Staphylococcus aureus Network Adaptive Platform Trial Protocol: new tools for an old foe. Clin Infect Dis. 2022;75(11):2027\u201334. https:\/\/doi.org\/10.1093\/cid\/ciac476.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"422_CR37","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1128\/aac.02371-13","volume":"58","author":"AM Casapao","year":"2014","unstructured":"Casapao AM, Davis SL, Barr VO, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58(5):2541\u20136. https:\/\/doi.org\/10.1128\/aac.02371-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"422_CR38","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/jac\/dks006","volume":"67","author":"TT Ho","year":"2012","unstructured":"Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS 2nd. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67(5):1267\u201370. https:\/\/doi.org\/10.1093\/jac\/dks006.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"422_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","volume":"19","author":"JC Lin","year":"2013","unstructured":"Lin JC, Aung G, Thomas A, Jahng M, Johns S, Fierer J. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother. 2013;19(1):42\u20139. https:\/\/doi.org\/10.1007\/s10156-012-0449-9.","journal-title":"J Infect Chemother"},{"issue":"5","key":"422_CR40","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ijantimicag.2013.07.005","volume":"42","author":"HM Polenakovik","year":"2013","unstructured":"Polenakovik HM, Pleiman CM. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents. 2013;42(5):450\u20135. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.07.005.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"422_CR41","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/jac\/dku085","volume":"69","author":"P Tattevin","year":"2014","unstructured":"Tattevin P, Boutoille D, Vitrat V, et al. Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study. J Antimicrob Chemother. 2014;69(7):2010\u20133. https:\/\/doi.org\/10.1093\/jac\/dku085.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"422_CR42","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ijantimicag.2014.07.024","volume":"44","author":"JA Paladino","year":"2014","unstructured":"Paladino JA, Jacobs DM, Shields RK, et al. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations. Int J Antimicrob Agents. 2014;44(6):557\u201363. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.07.024.","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"422_CR43","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","volume":"36","author":"G Sakoulas","year":"2014","unstructured":"Sakoulas G, Moise PA, Casapao AM, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014;36(10):1317\u201333. https:\/\/doi.org\/10.1016\/j.clinthera.2014.05.061.","journal-title":"Clin Ther"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-024-00422-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-024-00422-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-024-00422-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T17:08:13Z","timestamp":1718298493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-024-00422-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["422"],"URL":"https:\/\/doi.org\/10.1007\/s40801-024-00422-5","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"assertion":[{"value":"11 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jennifer Hammond, Michael Benigno, Wajeeha Ansari, and Jennifer Nguyen are employees of, and shareholders in, Pfizer. Nataly Bleibdrey is a former employee of Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"Data queries should be addressed to Premier Inc., which is an independent third party with rights to data availability in the Premier Healthcare Database. These data are proprietary, and the authors do not have permission to disseminate them; however, they can be obtained from the vendor at a cost. Please contact the vendor for additional information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Ethics committee approval was not required, as this was a retrospective secondary database study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Study concept and design: Jennifer Hammond, Wajeeha Ansari, and Jennifer Nguyen. Data analysis and interpretation: All authors. Critical review and revision of the manuscript: All authors. Final approval of the manuscript draft to be published: All authors. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}